BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
Subscribe To Our Newsletter & Stay Updated